HC Wainwright Predicts Stronger Earnings for Scholar Rock

Scholar Rock Holding Co. (NASDAQ:SRRK) – Research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Scholar Rock in a report released on Tuesday, November 26th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($1.57) per share for the year, up from their previous forecast of ($1.68). HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.40) per share. HC Wainwright also issued estimates for Scholar Rock’s FY2027 earnings at ($0.78) EPS and FY2028 earnings at $0.18 EPS.

Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. boosted their target price on shares of Scholar Rock from $18.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, October 14th. Piper Sandler upped their price objective on shares of Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. BMO Capital Markets increased their price objective on shares of Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a research report on Friday, October 11th. Wedbush boosted their target price on Scholar Rock from $40.00 to $47.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Truist Financial increased their price target on Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $40.43.

Scholar Rock Price Performance

Shares of SRRK opened at $38.15 on Thursday. The firm has a market cap of $3.57 billion, a PE ratio of -16.23 and a beta of 0.47. Scholar Rock has a 52-week low of $6.76 and a 52-week high of $43.38. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The business’s 50 day moving average price is $24.29 and its two-hundred day moving average price is $14.54.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Clearbridge Investments LLC purchased a new position in Scholar Rock in the second quarter worth $6,223,000. Candriam S.C.A. bought a new stake in shares of Scholar Rock during the 2nd quarter worth $6,201,000. Fisher Asset Management LLC boosted its holdings in shares of Scholar Rock by 593.6% in the 3rd quarter. Fisher Asset Management LLC now owns 734,019 shares of the company’s stock worth $5,879,000 after buying an additional 628,186 shares during the last quarter. Millennium Management LLC grew its position in Scholar Rock by 159.2% during the second quarter. Millennium Management LLC now owns 925,584 shares of the company’s stock valued at $7,710,000 after buying an additional 568,512 shares during the period. Finally, Marshall Wace LLP increased its holdings in Scholar Rock by 1,051.3% during the second quarter. Marshall Wace LLP now owns 487,285 shares of the company’s stock worth $4,059,000 after buying an additional 444,961 shares during the last quarter. 91.08% of the stock is owned by institutional investors.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Tracey Sacco sold 30,000 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $25.62, for a total transaction of $768,600.00. Following the transaction, the insider now directly owns 49,285 shares in the company, valued at approximately $1,262,681.70. This trade represents a 37.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Public Equities L.P. Invus sold 409,433 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the completion of the sale, the insider now owns 10,850,005 shares of the company’s stock, valued at approximately $417,616,692.45. The trade was a 3.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,823,322 shares of company stock valued at $56,411,627 over the last three months. Corporate insiders own 19.20% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.